Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2003 Aug;20(8):294-300.
doi: 10.1023/a:1024899806149.

Cost-effectiveness of recombinant versus urinary follicle-stimulating hormone in assisted reproduction techniques in the Spanish public health care system

Alberto Romeu  1 , Juan Balasch, José A Ruiz Balda, Pedro N Barri, Salim Daya, Jean P Auray, Gerald Duru, Ariel Beresniak, José A Peinado
Affiliations
Comparative Study

Cost-effectiveness of recombinant versus urinary follicle-stimulating hormone in assisted reproduction techniques in the Spanish public health care system

Alberto Romeu et al. J Assist Reprod Genet. 2003 Aug.

Abstract

Purpose: To evaluate the relative cost-effectiveness of recombinant and urinary follicle-stimulating hormone (FSH) in assisted reproduction techniques in the Spanish National Health Service.

Methods: Markov modelling was used to compare costs and outcomes of three complete treatment cycles using recombinant or urinary FSH for controlled ovarian stimulation. Cost and effectiveness estimates were obtained from the literature and from Spanish clinicians. A Monte Carlo technique was used to randomise the distribution of outcomes at each stage. The analysis was performed by passing a virtual population of 100,000 patients through the computer simulation in each of 5000 Monte Carlo simulations.

Results: The cost per pregnancy was Euro12,791+/-1202 ($11,346+/-1066) with recombinant and Euro13,007+/-1319 ($11,537+/-1170) with urinary FSH (p < 0.0001). The mean number of cycles per pregnancy was 4.69 and 5.21, respectively.

Conclusions: Recombinant FSH is more cost-effective than urinary FSH in the Spanish public health care system.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Loumaye E, Campbell R, Salat-Baroux J. Human follicle-stimulating hormone produced by recombinant DNA technology: A review for clinicians. Hum Reprod Update. 1995;1:188–199. - PubMed
    1. Daya S, Gunby J. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction. Hum Reprod. 1999;14:2207–2215. - PubMed
    1. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13:397–409. - PubMed
    1. Van Loon J, Liaropoulos L, Mousiama T. Economic evaluation of a recombinant follicle-stimulating hormone (Follitropin Beta, Puregon®) in infertile women undergoing in vitro fertilisation in Greece. Clin Pharmacoecon. 2000;19:201–211.
    1. Mantovani L, Belisari A, Szucs T. Pharmaco-economic aspects of in-vitro fertilisation in Italy. Hum Reprod. 1999;14:953–958. - PubMed

Publication types

Substances